(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
`(19) World Intellectual Property Organization A, | I
`International Bureau
`
`p
`
`(43) International Publication Date
`29 June 2006 (29.06.2006)
`
`WO 2006/067165 A2
`
` (10) International Publication Number
`
`(51) International Patent Classification:
`
`Notclassified
`
`(21) International Application Number:
`PC1/EP2005/057002
`
`(22) International Filing Date:
`21 December 2005 (21.12.2005)
`
`(25) Filing Language:
`
`(26) Publication Language:
`
`English
`
`English
`
`(30) Priority Data:
`04030770.4
`
`24 December 2004 (24.12.2004)
`
`EP
`
`(71) Applicant (for all designated States except DE, US):
`BOEHRINGER INGELHEIM INTERNATIONAL
`
`GMBH [DE/DE]; Binger Str. 173, 55216 Ingelheim Am
`Rhein (DE).
`
`(71) Applicant(for DE only): BOEHRINGER INGELHEIM
`PHARMA GMBH & CO. KG [DE/DE]; Binger Str. 173,
`55216 Ingelheim Am Rhein (DE).
`
`(72)
`(75)
`
`Inventors; and
`Inventors/Applicants (for US only): PARK, John, Ed-
`ward [US/DE]; Am Marktplatz 40, 88400 Biberach (DB).
`ROTH,Gerald, Jiirgen [DE/DE]; Akazienweg 47, 88400
`Biberach (DE). HECKEL, Armin [DE/DE]; Geschwis-
`ter-scholl-str. 71, 88400 Biberach (DE). CHAUDHARY,
`Nveed [GB/DE]; Kolping Strasse 27, 88400 Bibcrach
`(DE). BRANDL, Trixi [DE/DE]; Mailzerstrasse 8, 88447
`Warthausen (DE). DAHMANN, Georg [DE/DE]; Bahn-
`hofstrasse 14, 88448 Attenweiler
`(DE). GRAUERT,
`
`Matthias [DE/DE]; Osterbergstr.
`(DE).
`
`10, 88400 Biberach
`
`(74) Agent: HAMMANN,Heinz; Binger Str. 173, 55216 In-
`gelheim Am Rhein (DE).
`
`(81) Designated States (unless otherwise indicated, for every
`kind ofnational protection available): AE, AG, AL, AM,
`AT, AU, AZ, BA, BB, BG, BR, BW,BY, BZ, CA, CH, CN,
`CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
`GB, GD, GE, GH, GM, HR, HU,ID, IL, IN, IS, JP, KE,
`KG, KM,KN,KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
`LY, MA, MD, MG, MK, MN, MW,MX, MZ, NA, NG,NI,
`NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
`SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
`UZ, VC, VN, YU, ZA, 7M, ZW.
`
`(84) Designated States (unless otherwise indicated, for every
`kind ofregional protection available): ARIPO (BW, GH,
`GM,KB, 1.S, MW, MZ, NA, SD, SL, SZ, TZ, UG, 7M,
`ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
`European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
`FR, GB, GR, HU,IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
`RO,SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
`GN, GQ, GW, ML, MR, NE, SN, TD, TG).
`
`Published:
`without international search report and to be republished
`upon receipt of that report
`
`For two-letter codes and other abbreviations, refer to the "Guid-
`ance Notes on Codes and Abbreviations" appearing at the begin-
`ning of each regular issue of the PCT Gazette.
`
`(54) Title: MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
`
`R3
`
`(57) Abstract: The present inventionrelates to the use of
`indolinones of general formula (1) substituted in the 6 po-
`sition, wherein R, to Rs and X are defined as in claim 1,
`the isomers and the salts thereof, particularly the physiolog-
`ically acceptable salts thereof, as a medicamentfor the pre-
`vention or treatment of specific fibrotic diseases.
`
`
`
`
`
`
`
`WO2006/067165A2[IMMINININEIITINIINIETAAITMTTAATATT
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC
`
`
`
`
`
`
`DISEASES
`
`The present
`
`
`invention relates to a new use of indolinones
`
`
`
`of general formula
`
`R,
`
`N
`
`Ry
`
`Rp
`
`N
`
`=~
`
`NN
`
`Ry
`
`Rs
`
`x
`
`(I),
`
`substituted in the 6 position,
`
`
`
`diastereomers,
`
`
`
`the tautomers,
`
`the
`
`
`the mixtures thereof and
`
`
`
`the enantiomers,
`
`
`
`
`the salts thereof, particularly the physiologically
`
`acceptable salts thereof.
`
`
`
`BACKGROUND
`
`5
`
`10
`
`15
`
`20
`
`25
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`Compounds of
`
`the above
`
`
`
` formula I,
`general
`
`the tautomers,
`
`
`thereof
`
`the dias
`
`tereomers,
`
`the enantiomers,
`
`and the
`
`salts thereof,
`
`particu
`
`larly
`
`the mixtures
`
`
`the physiologically
`
` thereof,
`
`in particu lar an inhibiting ef
`
`
`acceptable salts
`
`
`
`have been described in WO
`
`01/27081 and WO 04/13099 as having valuable pharmacological
`
` Fect on various
`properti es,
`
`
`
`such as
`especially receptor tyrosine kinases
`kinases,
`
`
`P
`
`
`
`H
`
`GFLR and
`DGFRO, PDGFRB
`VEGFR2,
`EGFR,
`ER2,
`
`, FGFRI,
`
`FGFR3,
`
`
`CDK's
`
`(Cyclin
`
` Dependent
`
`as complexes of
`s uch as CDKi1,
`
`
`HGFR, as
`
`well
`
`10
`
`Kinases)
`
` D1, D2,
`
`
`with the
`CDK8 and CDK9
`
`
`
`93, E, F, Gl,
`
`CDK2,
`
`DK3,
`C
`
`
`ir speci
`fic cyclins
`
`CDK4,
`
`CDK5, CDK6,
`
`
`(A, Bl,
`
`
`B2,
`
`Cc,
`
`
`CDRK7,
`
`G2,
`
`and K)
`
`and
`
`to viral cyclin
`
` (cf. L.
`
`Mengtao in J. Virology
`
`71(3),
`
`1984-1991
`
`(1997)),
`
`in
`
`
` H,
`
` cells,
`
`
`
`he proliferati
`
`
`
`ar endothelial
`
`
`
`ion of
`the proliferat
`
`on of cultivated human cells,
`
`
`
`e.g.
`
`in
`
`angiogenesis, but
`
`other cells,
`
`in particular
`
`
`
`and on t
`
`15
`
`particul
`
`also on
`
`tumour c
`
` their us
`
`However,
`
`ells.
`
`none of
`
`e in the
`
`
` for
`
`these compounds have been described
`
`
` fibrotic
`the
`treatment or prevention of
`
`diseases
`
`
`referred to in the present
`
`invention.
`
`Remodeling is a normal response to tissue injury and
`
`in
`
`
`flammation that is observed in many tissues throughout
`
`
`
`the body. After resolution of
`
`
`of tissue damage,
`
`the tissue i
`
`original condition.
`
`
`
`
`Excessive uncontrol
`
`the infl
`ammation and repair
`
`ly returned to its
`Ss general
`
`
` led tissue repair or
`
`
`
`the failure to stop
`
` matrix componen
`
`remodeling when it is no longer
`
`fibrosis.
`
`Fibrosis is
`
`required leads
`
`characterized by excessive deposition
`
`
`
`ts and overgrowth of
`
`of extracellular
`
` roblasts. Fibrosis
`
`ib
`
`can occur in all tissues but is especi
`
`in
`
` ally prevalent
` to condition known as
`
`20
`
`25
`
`30
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`organs with
`
`
`frequent exposure to chemical and biological
`
`insults including the lung,
`
`
`and liver (
`Eddy,
`
`
`
`1996,
`
`J Am Soc Nephrol,
`
`skin,
`
`digestive tract,
`
`kidney,
`
`7(12):2495-503;
`
`
`Biol, 298:
`
`S5-9;
`
`Dacic et al.,
`
`2003,
`
`Am J Respir Cell Mol
`
`
`Rev Immunol,
`
`4(8):583-94).
`
`
`Fibrosis often
`
`Wynn, 2004,
`
`
`
` Nat
`
`
`function(s)
`
`of the organ
`
`ain
`
`fact,
`
`life-threatening
`
`such as idiopathic pulmonary
`
`
`limited to organ transplantat
`
`liver cirrhosis,
`
`or renal
`
`cen
`
`for these diseases are of
`
`
`
`
` scleroderma,
`
`severely compromises the normal
`
`and many fibro
`tic diseases are,
`
`
`or severel y disfiguring,
`
`
`fibrosis (
`IPF),
`
`fibrosis.
`
`Treatment options
`
`procedure.
`
`tion,
`
`a risky and expensive
`
`
`
`CULre
`
`A large body of litera
`implicates the p
`
`
` factor
`growth factor
`(PDGF),
`vasc
`
`
`
`ial
`
`
`
`
`
` g
`
`
`
`
`fibroblast growth
`_~
`
`
`rowth facto
`(VEGF),
`
`latelet—derived
`
`
`
`(FGF),
`
`epidermal growth
`
`
`trans
`and
`forming grow
`factor
`(EGF),
`
`
`
`
`th factor
`families
`in the inducti
`
`th
`
`
`
`
`factor beta
`~
`
`
`
`pe
`
`on o
`
`
`
`
`rsistence of
`
`
`(TGFb)
`
`grow
`
`10
`
`15
`
` ular endothe]
`
`
`fibrosis
`
`(Levitzki,
`
`Cy
`
`15 (4) :229-35;
`
`Sstrutz et
`
`
` al.,
`
`tokine Growth
`
`Factor Rev,
`
`Kidney
`
`Intl,
`
`2000,
`
`Strutz et al.,
`
`2003,
`
`Springer Semin
`
`Immunopathol,
`
`24:459-
`
`76;
`
`Rice et al
`
`7
`
`1999,
`
`Amer J Pathol
`
`, 155(1) 3213-221;
`
`
`Broekelmann et
`
`al.,
`
`1991,
`
`Proc Nat Acad Sci,
`
`88:6642-6;
`
`
`
`
`
`2004,
`
`57:1521-38;
`
`
`
`Wynn,
`
`2004,
`
`Nat
`
`Rev Immunol,
`
`4(8):583-94).
`
`
`
`20
`
`295
`
`
`
`
`
`
`EGF and
`PDGF,
`
`Dmp
`H
`H
`
`
`family members are potent mitogens
`
`mesenchymal cells such as smooth muscle cel
`
` for
`
` ls,
`
` Basic Res Cardiol,
`
` myo
`fibroblasts
`
`
`and fibroblasts
`
`(
`
` Benit
`
`to et al., 1993, Growth
`
`Regul 3(3):172-
`
`9; Simm et al,
`
`1998,
`
`30
`
`93(S3):40-3;
`
`Klagsburn,
`
`Prog Growth Factor Res,
`
`1989,
`
`1(4):207-35; K
`
`9(8):1464-73),
`
`irkland et al.,
`
`the very cells which supplant normal tissue
`
`1998,
`
`J Am Soc Nephrol,
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`in fibrosis and are believed to play a role in tissue
`
`remodeling (Abboud, 1995, Annu Rev Physiol., 57:297-309;
`
`Jinnin et al., 2004, J Cell Physiol, online; Martinet et
`
`
`al., 1996, Arch Toxicol 18:127-39; Desmouliere, Cell
` Biology International, 1995, 19:471-6; Jelaska et al.,
`
`
`
`
`
`
`
`
`Springer Semin Immunopathol, 2000, 21:385-95).
`
`
`
`
`
`
`
`Inhibition of PDGF attenuates both liver fibrosis and lung
`
`
`fibrosis in experimental models, suggesting fibrosis in
`
`
`
`
`
`different organs may have a common origin (Borkham—
`
`
`
`Kamphorst et al., 2004, Biochem Biophys Res Commun; Rice et
`
`
`
`
`
`
`An EGF receptor
`al., 1999, Amer J Pathol, 155(1):213-221).
`
`kinase inhibitor was also active in this lung fibrosis
`
`
`
`
`model. Three-fold overexpression of an EGF family member,
`
`
`
`
`HB-EGF,
`in mouse pancreas islets was sufficient to cause
`
`development o
`Fibrosis in both the exocrine and endocrine
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`compartments
`
`(Means et al., 2003, Gastroenterology,
`
`124 (4) :1020-36).
`
`
`Similarly, FGF1/FGF2-deficient mice show dramatically
`
`
`decreased liver fibrosis after chronic carbon tetrachloride
`
`(CC14) exposure (Yu et al., 2003, Am J Pathol, 163(4):1653-
`
`62). FGF expression is increased in human renal
`
`
`interstitial
`fibrosis where it strongly correlates with
`
`
`
`
`
`
`
`
`
`
`interstitial scarring (Strutz et al., 2000, Kidney Intl,
`
`57:1521-38) as well as in a model of experimental
`
`
`
`
`fibrosis (Barrios et al., 1997, Am J Physiol, 273 (2 Pt
`
`1):L451-8), again lending credence to the idea that
`
`
`
`fibrosis in various tissues has a common basis.
`
`
`
`
`In addition, elevated levels of VEGF have been observed in
`
`several studies in persons with asthma (Hoshino et al.,
`
`
`lung
`
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`—~
`
`5 -
`
`
`2001, J Allergy Clin Immunol 107:1034-39; Hoshino et al.
`
`2001, J Allergy Clin Immunol 107:295-301; Kanazawa et al.
`
`
`
`
`
`
`
`
`,
`
`,
`
`
`
`
`
`2002, Thorax 57:885-8; Asai et al.,
`
`
`J Allergy Clin Immunol
`
`110:571-5, 2002; Kanazawa et al., 2004, Am J Respir Crit
`
`
`
`
`Care Med, 169:1125-30). Inducible expression of VEGF ina
`
`transgenic mouse model
`
`induces an asthma-like phenotype,
`
`edema, angiogenesis and smooth muscle hyperplasia (Lee et
`
`al., 2004, Nature Med 10:1095-1103).
`
`
`
`
`Finally, TIGFb stimulates production of extracellular matrix
`
`proteins including
`
`believed to play an
`
`tissues
`
`(Leask et al
`
`fibronectin and collagens and is
`
`
`important role in fibrosis in many
`
`
`
`
`l., 2004, FASEB J 18(7):816-27; Bartram
`
`
`
`
`et al.,
`
`2004,
`
`Chest
`
`125(2):754-65; Strutz et al., 2003,
`
`
`
`
`Immunopathol, 24:459-76; Wynn, 2004, Nat Rev
`
`
`
`Inhibitors of
`
`Springer Semin
` Immunol,
`
`4(8):583-94).
`
`
`
`TGFb production and
`
` fibrosis
`signaling pathways are active in a number of
`
`
`
`animal
`
`models
`
`(Wang
`
`
`et al., 2002, Exp
`
`Lung Res,
`
`28:405-17;
`
`Laping,
`
`2003,
`
`Curr Opin Pharmacol,
`
`3 (2) 2204-8).
`
`in
`
`As summarized above,
`
`
`factors are upregulated
`several growth
`
`
`
` factor seems to
`inhibition of a single
`fibrosis and the
`
`
`
`
`in the fibrosis models.
`Fibrosis
`reduce the severity of
`
`
`
` NVI
`
` ON
`SUMMARY OF THE
`
` we
`found that the compounds of above general
`
`Surprisingly,
`
`
`
`
` formula I
`
`
`are ef
`Fective in the treatment or prevention of
`
`
`Fibrotic diseases.
`specific
`
`
`
`10
`
`15
`
`20
`
`295
`
`30
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`The present inven
`
`
`tion thus relates to the use of the
`
`
`
`
`
`
`for the preparation of
`formula
`compounds of above general
`
`
`
`
`a medicament £
`or the treatment or prevention of specific
`
`
`
`
`fibrotic diseases.
`
`The present
`
`invention also
`
`
`relates to a method for the
`
`
`treatment or prevention of specific
`
`administration
`
`to a pati ent
`
`
`composition comprising a compound of above
`
`
`
`a I,
`formu]
`general
`
`together with a pharmaceutically
`
`in need
`
`
`thereof of a
`
`fibrotic diseases, by
`
`
`
`
`pharmaceutical
`
`
`10
`
`15
`
`20
`
`suitable carri
`
`er. The expression
`
`"patient" is meant to
` preferably the human
`
`comprise the mammalian animal body,
`
`body.
`
`
`vention further relates to a pharmaceutical
`in
`The present
`
`composition for the treatment or prevention of specific
`
`
`
`a IT alone or in combination with one or more
`general
`formu]
`
`
`
`
`
`
` fibrotic diseases which comprises a compound of above
`
`further therapeutic agents.
`
`
`T
`
`
`
`
`
`
`
`
`
`
`TH
` NVENT
`
`DETAILLED DESCRIPTION OF
`
`ON
`
`
`In accordance with the present invention,
`
`
`
`Formula
`above general
`are the compounds
`
`295
`
`
`the compounds of
`
`

`

`WO 2006/067165
`
`PCT,
`
`/EP2003/057002
`
`in which
`
`X denotes an oxygen or sulphur atom,
`
`Ri, denotes a hydrogen atom or a prodrug group such as a
`
`Cy-a-alkoxycarbonyl or Cy-4a-alkanoyl group,
`
`
`
`Ro denotes a carboxy group,
`
`Ci-e-alkoxy-—carbonyl group,
`
`a straight-chain or branched
`
`a C47-cycloalkoxy—carbonyl or an
`
`aryloxycarbonyl group,
`
`10
`
`15
`
`t-chain or branched C;-¢-al
`
`which is
`
`terminally substituted in
`
`
`a straigh
`
` aminocarbonyl,
`
`phenyl, heteroaryl, carboxy, Ci-3;-al
`
`Ci-3-alkylamino-carbonyl or
`
`
`
`Lkoxy-carbonyl group,
`
`the alkyl moiety by a
`
`Lkoxy—carbonyl,
`
`
`
`20
`
`di-(Ci-3-alkyl)-aminocarbonyl group,
`
`a straigh
`
`which is
`
`
`
`t-chain or branched C2-~.-alkoxy-—carbonyl group,
`
`terminally substituted in the alkyl moiety by a
`
`chlorine atom or a hydroxy,
`
`Ci-3-alkoxy, amino,
`
`25
`
`Cy-3-alkylamino or di-(C,-3-alkyl)—-amino group,
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`an aminocarbonyl or methylaminocarbonyl group, an
`
`ethylaminocarbonyl group optionally substituted in the 2
`
`
`position of the ethyl group by a hydroxy or C,-3-alkoxy
`
`group or a di-(Ci-»-alkyl)-aminocarbonyl group,
`
`R3 denotes a hydrogen atom,
`
`a Ci-s-alkyl, C37-cycloalkyl,
`
`
`trifluoromethyl or heteroaryl group,
`
`a phenyl or naphthyl group, a phenyl or naphthyl group
`
`mono-— or disubstituted by a fluorine, chlorine, bromine or
`
`
`
`
`
`iodine atom, by a trifluoromethyl, C,-3-alkyl or C,-3-alkoxy
`
`group, whilst
`in the event of disubstitution the
`
`
`
`substituents may be identical or different and wherein the
`
`
`
`
`
`
`
`
`
`10
`
`15
`
`20
`
`
`
`
`
`
`
`abovementioned unsubstituted as well as the mono- and
`
`disubstituted phenyl and naphthyl groups may additionally
`
`be substituted
`
`
`
`by a hydroxy, hydroxy—Cyi-3-alkyl or C,-3-alkoxy—C,_3-alkyl
`
`group,
`
`by a cyano, carboxy, carboxy—Ci-:-alkyl, Ci-s-alkoxycarbonyl,
`
`aminocarbonyl, Ci-3s-alkylamino-carbonyl or di- (Ci-3-alkyl)-
`
`
`
`aminocarbonyl group,
`
`295
`
`by a nitro group,
`
`
`by an amino, Ci-3-alkylamino, di- (Ci-3-alkyl)-amino or amino-
`
`Cy-3-alkyl group,
`
`30
`
`by a Ci-3-alkylcarbonylamino, N-(C,-3-alkyl) —-Ci-3-alkyl-
`
`carbonylamino, C)-3-alkylcarbonylamino—C,-3:-alkyl,
`
`N- (Ci-3-alkyl)—-Ci-3-alkylcarbonylamino—-C,-3-alkyl, Ci-3-alkyl-
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`sulphonylamino, Ci-3-alkylsulphonylamino-Ci-3-alkyl,
`
`N- (Ci-3-alkyl)—-C.i-3:-alkylsulphonylamino—Ci_-3-alkyl or
`
`aryl-C,_-3,;-alkylsulphonylamino group,
`
`
`
`by a cycloalkylamino, cycloalkyleneimino, cyclo-
`
`alkyleneiminocarbonyl, cycloalkyleneimino—Ci-:-alkyl,
`
`
`
`
`
`
`
`cycloalkyleneiminocarbonyl-C, 3-alkyl or
`
`cycloalkyleneiminosulphonyl—-C,-3-alkyl group having 4 to 7
`
`ring members in each case, whilst in each case the
`
`10
`
`
`methylene group in position 4 of a 6- or 7-membered
`
`cycloalkyleneimino group may be replaced by an oxygen or
`
`sulphur atom, by a sulphinyl, sulphonyl,
`
`-—-NH
`
`or -N(Ci-3-alkyl) group,
`
`15
`
`
`or by a heteroaryl or heteroaryl—C;-3-alkyl group,
`
`Rz denotes a C3-7-cycloalkyl group,
`
`
`whilst the methylene group in the 4 position of a 6- or 7-
`
`20
`
`membered cycloalkyl group may be substituted by an amino,
`
`Cy-3-alkylamino or di-(Ci-3-alkyl)-amino group or replaced by
`
`an —-NH or -N(Ci-2-alkyl) group,
`
`295
`
`30
`
`or a phenyl group substituted by the group Rs, which may
`
`
`additionally be mono- or disubstituted by fluorine,
`
`
`
`
`
`
`
`chlorine, bromine or iodine atoms, by Ci-5-alkyl,
`
`
`trifluoromethyl, hydroxy, Ci-3-alkoxy, carboxy,
`
`
`
`Cy-3-alkoxycarbonyl, amino, acetylamino,
`
`Cy-3-alkyl—-sulphonylamino, aminocarbonyl,
`
`Cy-3-alkyl—-aminocarbonyl, di-(Ci-3:-alkyl)-aminocarbonyl,
`
`aminosulphonyl, Ci-3-alkyl-aminosulphonyl,
`
`di-(Cy-3-alkyl)-aminosulphonyl, nitro or cyano groups,
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`
`
`wherein the substituents may be identical or different and
`
`wherein
`
`
`Re denotes a hydrogen, fluorine, chlorine, bromine or
`
`iodine atom,
`
`a cyano, nitro, amino, ( 5s-alkyl, C3 7-cycloalkyl,
`
`
`trifluoromethyl, phenyl,
`
`tetrazolyl or heteroaryl group,
`
`
`
`
`
`
`
`the group of
`formula
`
`oH
`
`0
`
`N
`
`NH
`
`O f
`
`wherein the hydrogen atoms bound to a nitrogen atom may in
`
`
`each case be replaced independently of one another by a
`
`Cyi-3-alkyl group,
`
`a C, 3-alkoxy group,
`
`Cy-3-alkoxy, amino-Czo-3-alkoxy, Ci-3-alkylamino-—Cz-3-alkoxy,
`
`di-(Cy-3-alkyl)—-amino-—C2z_-3-alkoxy, phenyl—C;-3-alkylamino—
`
`a C, 3-alkoxy—C, 3;3-alkoxy, phenyl-—
`
`
`
`
`
`
`Co-3-alkoxy, N-(Ci-3-alkyl) -pheny1-—C,_3-alkylamino-—Cyz_-3—-alkoxy,
`
`Cs-7-cycloalkyleneimino—Co_3-alkoxy or C,-3-alkylmercapto
`
`group,
`
`a carboxy, Ci4a-alkoxycarbonyl, aminocarbonyl, Ci-3-alkyl-
`
`amino-carbonyl, N-(Ci-s-alkyl1)—-Ci_-3-alkylaminocarbonyl,
`
`phenyl-Ci-3-alkylamino-carbonyl,
`
`N- (Cy_-3-alkyl)—-phenyl—C;_2z-alkylamino-carbonyl,
`
`piperazinocarbonyl or N-(C,-3-alkyl) -piperazinocarbony]
`
`group,
`
`10
`
`15
`
`20
`
`25
`
`

`

`WO 2006/06
`
`7165
`
`PCT/EP2005/057002
`
`a Ci-3-alkylaminocarbonyl
`
`or N- (Ci-s-alkyl)-
`
`Ci-3-alkylaminocarbony]
`
`group wherein an alkyl moiety is
`
`substituted by a carboxy or C.-3;-alkoxycarbonyl group or in
`
`the 2 or 3 position by a di-(Ci-s-alkyl)-amino, piperazino,
`
`N- (Ci-3-alkyl)-piperazino or a 4-
`
`to 7-membered
`
`cycloalkyl eneimino group,
`
`
`a C3-7-cycloalkyl-carbonyl group,
`
`
`
`10
`
`
`wherein the methylene group in the 4 position of the 6- or
`
`moiety may be substituted by an
`7-membered cycloalkyl
`
`Ci-3-alkylamino
`or di-(Ci-3s-alkyl)-amino group or
`
`amino,
`
`replaced by an —-NH or —-N ( Cy-3-alkyl)
`
`group,
`
`15
`
`a 4- to 7-membered cycloalkyleneimino group wherein
`
`a methylene group linked to the imino
`
`by a carbonyl or sulphonyl group or
`
`group may be replaced
`
`20
`
`the cycloalkylene moiety may be
`
`
`fused to a phenyl ring or
`
`one or two hydrogen atoms may each be
`
`replaced by a Ci-3-
`
`alkyl group and/or
`
`295
`
`
`in each case the methylene group in the 4 position of a 6-
`
`or 7-membered cycloalkyleneimino group may be substituted
`
`by a carboxy, C,-3-alkoxycarbonyl, aminocarbonyl,
`
`)-aminocarbonyl,
`ky]
`Cy-37-al
`
`ky]
`kylaminocarbonyl, di-(Ci_3-al
`
` l-—C,-3-al] ky] amino group or
`
`amino or N-(C)-3-al
`phenyl]1—Cy1-3-a] ky]
`
`
`phenyl]
`
`)-
`
`30
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`may be replaced by an oxygen or sulphur atom, by a
`
`sulphinyl,
`
`
`
`
`
`sulphonyl, —-NH,
`
`-—-N(Cyi-3-alkyl),
`
`-N(phenyl),
`
`-N(C,_;-alkyl-car
`
`bonyl) or -N(benzoyl) group,
`
`a Ci-4-alkyl group substituted by the group R;7, wherein
`
`R7 denotes a C3-7-cycloalkyl group,
`
`
`
`10
`
`
`whilst the methylene group in the 4 position of a 6- or 7-
`
`membered cycloalkyl group may be substituted by an amino,
`
`Cy-3-alkylamino or di-(Ci-3-alkyl)-amino group or replaced by
`
`
`
`
`
`an -NH or -N(Ci-3-alkyl) group or
`
`15
`
`in a 5- to 7-membered cycloalkyl group a —(CH2)2z group may
`
`be replaced by a -CO-NH group,
`
`a —(CH2)3 group may be
`
`replaced by a —NH-CO-NH or —CO-NH-CO group or a —(CHb»)a4
`
`group may be replaced by a —-NH-CO-NH-CO group, whilst
`
`in
`
`each case a hydrogen atom bound to a nitrogen atom may be
`
`
`
`20
`
`replaced by a Ci-3-alkyl group,
`
`an aryl or heteroaryl group,
`
`295
`
`30
`
`a hydroxy or C,-z-alkoxy group,
`
`
`
`
`
`an amino, Ci-7-alkylamino, di-(Ci-7-alkyl) -amino,
`
`phenylamino, N-phenyl-C,-3-alkyl-amino, phenyl—C;-3-alkyl—-
`
`amino, N-(Ci_-3-alkyl) —phenyl1-—-C)_3-alkylamino or di-
`
`(ephenyl—Ci-3-alkyl)-amino group,
`
`an @-hydroxy-—Cs-3,-alkyl-amino, N-(C,-3-alkyl) -@-hydroxy—
`
`Co-3-alkyl—-amino, di- (@-hydroxy—Cz-3-alkyl) -amino,
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`di-(@- (C1-3s-alkoxy) -—Co-3-alkyl)-amino or N-(dioxolan—
`
`2-y1l)—-Ci-3-alkyl-amino group,
`
`a C,;-,;-alkylcarbonylamino-Cp_3-alkyl-amino or
`
`Cy-3-alkylcarbonylamino-—Co-3-alky1—N- (Ci-3-alkyl)-amino group,
`
`a C,-3;-alkylsulphonylamino, N—-(Cy_3-alkyl) —Cy,_3-alkyl—-
`
`sulphonylamino, Ci-3-alkylsulphonylamino-—Cz2-3-alkyl-amino or
`
`
`
`Cy, 3-alkylsulphonylamino-—C, 3:-alky1—-N-(C; 3-alkyl) -—amino
`
`10
`
`group,
`
`a hydroxycarbonyl-C,_-3-alkylamino or N-(Ci-3-alkyl)-
`
`hydroxycarbonyl—Ci_3-alkyl-amino group,
`
`15
`
`a guanidino group wherein one or two hydrogen atoms may
`
`each be replaced by a Ci-3-alkyl group,
`
`
`
`
`
`a group of
`formula
`
`20
`
`—N (Rg) -CO- (CH2) n-R9
`
`
`
`
`
`(It),
`
`wherein
`
`Rg denotes a hydrogen atom or a Ci-3-alkyl group,
`
`25
`
`30
`
`
`n denotes one of the numbers 0, 1,
`
`2 or 3 and
`
`
`
`Rg denotes an amino, C,4-alkylamino, di-(Ci-4-alkyl)-amino,
`
`phenylamino, N-(Ci-a-alkyl)-phenylamino, benzylamino,
`
`N- (Ci-,-alkyl)-benzylamino or Cis.-alkoxy group,
`
`a 4- to 7-
`
`membered cycloalkyleneimino group, whilst in each case the
`
`methylene group in the 4 position of a 6- or 7-membered
`
`
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`14
`
`cycloalkyleneimino group may
`
`be replaced by an oxygen or
`
`sulphur atom, by a sulphinyl,
`
`
`
`sulphonyl, —-NH, —-N(C._-3;-alkyl),
`
`bonyl) or -N(benzoyl) group,
`
`
`or, if
`
`n denotes one of the
`
`—-N(phenyl),
`
`-N(Ci,_;-alkyl-car
`
`
`
`
`
`numbers 1,
`
`2 or 3,
`
`it may also denote a hydrogen atom,
`
`
`
`
`
`a group of
`formula
`
`—N (R19) — (CH2) m7 (CO) g9-R11
`
`
`
`
`
`
`
`(
`
`dy
`
`wherein
`
`arylcarbonyl,
`
`a Cyi_3-alkyl
`
`group,
`
`a
`
`phenyl-Ci-3-alkyl-carbonyl,
`
`arylsulphonyl or phenyl—-Ci-3-al-
`
`
`
`Rio de notes a hydrogen atom,
`
`Cy-3-alkylcarbonyl,
`
`
`
`Cyi-2-alkylsulphonyl,
`
`
`
`
`
`
`
`kylsulphonyl group,
`
`
`m denotes one of the numbers
`
`1, 2,
`
`3 or 4,
`
`o denotes the number 1 or,
`
`
`£m denotes one of the numbers
`
`i
`
`2,
`
`3 or 4,
`
`o may also denote
`
`the number
`
`0 and
`
`Ri, denotes an amino, Ci-4-alk
`
`ylamino, di-(Ci-4-alkyl)-amino,
`
`phenylamino,
`
`N- (Ci-4-alkyl)-benzylamino,
`
`N- (Cy-a-alkyl)—-phenylamino,
`
`benzylamino,
`
`
`
`Ci-4-alkoxy or
`
`Cyi-3-alkoxy—Ci-3-alkoxy group,
`
`a di-(Ci-4-alkyl) -amino-Ci_-3-
`
`
`
`alkylamino group optionally substituted in the
`
`
`
`
`
`to 7-membered
`
`by a Ci-3-alkyl group or a 4-
`
`cycloalkyleneimino group, wherein the cycloalkylene moiety
`
`
`may be fused to a phenyl ring or in each case the methylene
`
`group in the 4 position of a 6—- or 7-membered
`
`cycloalkyleneimino group may be replaced by an oxygen or
`
`
`
`1 position
`
`
`
`
`
`10
`
`15
`
`20
`
`25
`
`30
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`sulphur atom, by a sulphinyl,
`
` sulphonyl, —-NH, —-N(Ci-3-alkyl), -N(phenyl), —-N(Ci-3:-alkyl-car
`
`bonyl) or -N(benzoyl) group,
`
`a Cya-j7-cycloalkylamino, Cy-7-cycloalky1l—C;-3-alkylamino or
`
`
`Ca-y-cycloalkenylamino group wherein position 1 of the ring
`
`
`
`is not
`
`involved in the double bond and wherein the
`
`abovementioned groups may each additionally be substituted
`
`at the amino-nitrogen atom by a Cs-7-cycloalkyl, Ce-4-alkenyl
`
`10
`
`Or Cyi-4-alkyl group,
`
`a 4- to 7-membered cycloalkyleneimino group, wherein
`
`
`
`
`
`
`
`
`
`the cycloalkylene moiety may be fused to a phenyl group or
`
`imidazolo,
`
`thiazolo, pyridino, pyrazino or
`
`
`
`to an oxazolo,
`
`
`pyrimidino group optionally substituted by a fluorine,
`
`chlorine, bromine or iodine atom, by a nitro, C;-3-alkyl,
`
`Ci-3-alkoxy or amino group, and/or
`
`15
`
`295
`
`30
`
`20
`
`one or two hydrogen atoms may each be replaced by a
`
`Cy-3-alkyl, Cy-;-cycloalkyl or phenyl group and/or
`
`the methylene group in the 3 position of a 5-membered
`
`cycloalkyleneimino group may be substituted by a hydroxy,
`
`
`
`hydroxy—Ci-3-alkyl, C1-3-alkoxy or C,-3-alkoxy-—Ci-3-alkyl
`
`group,
`
`
`
`
`the methylene group in the 3 or 4 position of a 6- or 7-
`
`membered cycloalkyleneimino group may in each case be
`
`substituted by a hydroxy, hydroxy—-C;3-alkyl, C,-3-alkoxy,
`
`Cy-3-alkoxy—Ci-s-alkyl, carboxy, Ci-4-alkoxycarbonyl,
`
`carbonyl, Ci-3-alkylaminocarbonyl, di-(Ci-3-alkyl)-
`
`amino—
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`aminocarbonyl, phenyl-C,-3-alkylamino or N-(Ci-3-alkyl)-—
`
`phenyl—-Ci-3-alkyl-amino group or
`
`may be replaced by an oxygen or sulphur atom, by a
`
`sulphinyl, sulphonyl, —-NH, —N(C,-3-alkyl-
`
`),
`
`),
`
`-N(phenyl), —-N(phenyl-Ci-3z-alkyl-
`
`-N(Cy1 3-alkyl-carbonyl-), —-N(C,1 a-alkyl-—
`
`
`
`
`
`hydroxy-carbonyl—-),
`
`-N(Cy-4-alkoxy-—carbonyl-—-), —-N(benzoyl-)
`
`or —-N(phenyl—Ci-3-alkyl—-carbonyl-) group,
`
`wherein a methylene group linked to an imino-nitrogen atom
` of the cycloalkyleneimino group may be replaced by a
`
`carbonyl or sulphonyl group or in a 5- to 7-membered
`
`monocyclic cycloalkyleneimino group or a cycloalkyleneimino
`
`
`group fused to a phenyl group the two methylene groups
`
`linked to the imino-nitrogen atom may each be replaced by a
`
`
`
`10
`
`15
`
`carbonyl group,
`
`20
`
`or Re denotes a Ci-4-alkyl group which is substituted by a
`
`carboxy, Ci-3-alkoxycarbonyl, aminocarbonyl,
`
`Ci-3-alkylaminocarbonyl or di-(Ci-3-alkyl) -aminocarbony]
`
`group or by a 4- to 7-membered cycloalkyleneiminocarbonyl
`
`group,
`
`295
`
`an N- (Cyi-3-alkyl)—-C2-4-alkanoylamino group which is
`
`additionally substituted in the alkyl moiety by a carboxy
`
`or Cy-3-alkoxycarbonyl group,
`
`30
`
`
`
`
`
`a group of
`formula
`
`—N (R12) —CO-(CH2) p-R1 3
`
`
`(LV),
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`17 -
`
`wherein
`
`group or a Ci-3-alkyl group terminally substituted by a
`
`phenyl, heteroaryl,
`trif]l
`ucoromethyl,
`
`a Ci-e-alkyl or C3-7-cycloalkyl
`
`hydroxy, Ci-3-alkoxy,
`
`Riz denotes a hydrogen atom,
`
`
`
`
`
`
`
`a—-alkylamino-carbonyl,
`aminocarbonyl, Ci
`
`amino-carbonyl, Ci_-3-alkyl]
`-carbonyl, Ci
`
`di- (Cz, 4-alkyl)-
`
`-3-alkyl-sulphonyl-
`
`
`
`
`
`amino,
`
`10
`
`N- (Ci-3-alkyl) -Ci-3-alkyl-sulphonylamino,
`
`Ci-3-alkyl-aminosulphonyl or di-(Ci-3-alkyl) -aminosulphonyl
`
`group and
`
`
`p denotes one of the numbers
`
`0, 1,
`
`2 or 3 and
`
`15
`
`Ri3
`
`or,
`
`
`assumes the meanings of the abovementioned group Rj),
`
`
`
`if p denotes one of
`
`the numbers 1,
`
`2 or 3, it may also
`
`denote a hydrogen atom,
`
`
`
`
`
`Formula
`a group of
`
`—N (R14) —(CH2) g (CO) r-R15
`
`(V),
`
`wherein
`
`Rig denotes a hydrogen atom,
`
`Cyi-3-al kyJ
`carbonyl,
`
`arylcarbonyl,
`
`a Ci-.-alkyl group, a
`
`phenyl-Ci-3-alkylcarbonyl,
`
`heteroarylcarbonyl,
`
`
`
`Cy-a-alkylsulphonyl, aryl]
`
`sulphonyl,
`
`heteroaryl—Cy-3-alkylcarbonyl,
`
`
`
`
`
`
`
`
`phenyl-C;-3-alkylsulphonyl,
`
`heteroarylsulphonyl or
`
`heteroaryl-C, :-alkyl-sulphonyl group,
`
` 1, 2,
`
`3 or 4,
`
`
`q denotes one of
`
`the numbers
`
`20
`
`25
`
`30
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`
`r denotes the number 1 or, if gq is one of the numbers 2,
`
`3
`
`or 4, it may al so denote the number
`
`0O and
`
`Ris
`
`assumes the meanings of the abovementioned group R;,
`
`
`
`
`
`
`
`a group of
`formula
`
`10
`
`—N (R16) —SO2-R17
`
`
`(VI),
`
`wherein
`
`
`
`Rig denotes a hydrogen atom or a Cyi-4,-alkyl group optionally
`
`terminally substituted by a cyano,
`
`
`trifluoromethyl]
`
`N- (Ci-3-alkyl ) -t
`
`—carbonylamino or
` rifluoromethyl-carbonyl-amino group and
`
`
`
`15
`
`20
`
`25
`
`30
`
`Riz denotes a Ci-3-alkyl group,
`
`substituted by a di- (Ci-3-alkyl)-
`an amino group
`
`amino—Ci-3-alkyl]
`-—carbonyl or di-(C,-3-alkyl)—-
`
`
`
`
`
`amino—C;-3-—alky] -sulphonyl group and a di-(Ci-3-alkyl)-
`
`aminocarbonyl—-C;-3-alkyl group,
`
`or an N-(C,-3-alkyl)—-Ci-s-alkylsulphonylamino or
`
`
`
`
`
`N- (Ci-3-alkyl)-phenylsulphonylamino group wherein the alkyl
`
`moiety is addit
`
`group,
`
`ionally substituted by a cyano or carboxy
`
`wherein all the
`
`
`single-bonded or fused phenyl groups
`
`contained in the groups mentioned under Re may be mono- or
`
`
`disubstituted by fluorine, chlorine, bromine or iodine
`
`
`
`
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`
`atoms, by Ci-s-alkyl,
`trifluoromethyl, hydroxy, Ci-3-alkoxy,
`
`carboxy, Ci-3-alkoxycarbonyl, aminocarbonyl,
`
`Cy-4-alkylamino-carbonyl, di-(Cy4-alkyl)-amino-carbonyl,
`
`aminosulphonyl, Ci-3-alkyl-aminosulphonyl,
`
`di-(Cy-3-alkyl)—-aminosulphonyl, Ci-3-alkyl—-sulphonylamino,
`
`
`
`nitro or cyano groups, wherein the substituents may be
`
`
`
`
`
`identical or different, or two adjacent hydrogen atoms of
`
`the phenyl groups may be replaced by a methylenedioxy
`
`
`
`10
`
`15
`
`20
`
`295
`
`group,
`
`and
`
`Rs denotes a hydrogen atom or a C;-3-alkyl group,
`
`wherein by an aryl group is meant a phenyl or naphthyl
`
`
`group optionally mono- or disubstituted by a fluorine,
`
`
`
`chlorine, bromine or iodine atom, by a cyano,
`
`
`trifluoromethyl, nitro, carboxy, aminocarbonyl, Cj,-3-alkyl
`
`
`
`or Cyi-3-alkoxy group and
`
`by a heteroaryl group is meant a monocyclic 5- or 6-
`
`membered heteroaryl group optionally substituted by a Ci-3-
`
`alkyl group in the carbon skeleton, wherein
`
`the 6-membered heteroaryl group contains one,
`
`two or three
`
`nitrogen atoms and
`
`
`the 5-membered heteroaryl group contains an imino group
`
`optionally substituted by a C,-3-alkyl or phenyl-—-C;,-3-alkyl
`
`
`
`30
`
`group, an oxygen or sulphur atom or
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`
`an imino group optionally substituted by a Ci-3-alkyl or
`
`phenyl1-Ci-3-alkyl group or an oxygen or sulphur atom and
`
`additionally a nitrogen atom or
`
`an imino group optionally substituted by a Cy-3-alkyl or
`
`phenyl-Ci-z-alkyl group and two nitrogen atoms,
`
`and moreover a phenyl ring may be fused to the
`
`abovementioned monocyclic heterocyclic groups via two
`
`adjacent carbon atoms and the bonding takes place via a
`
`
`nitrogen atom or via a carbon atom of
`
`the heterocyclic
`
`
`moiety or a fused phenyl ring,
`
`
`some or all of the hydrogen atoms in the abovementioned
`
`alkyl and alkoxy groups or in the alkyl moieties contained
`
`
`
` optionally being
`in the above-defined groups of Formula
`
`
`
`
`replaced by fluorine atoms,
`
`the saturated alkyl and alkoxy moieties with more than 2
`
`carbon atoms which are present in the groups defined
`
`
`
`hereinbefore also include the branched isomers thereof,
`
`
`
`
`
`
`
`such as for example the isopropyl,
`
`tert.butyl,
`
`isobutyl
`
`group, unless otherwise stated,
`
`and
`
`
`
`Saturated N-heterocycle such as trogen atom, e.g. a
`
`
`additionally the hydrogen atom of any carboxy group present
`
`or a hydrogen atom bound to a nit
`
`hydrogen atom of an amino, alkylamino or
`
`imino group ora
`
`the piperidinyl group, may
`
`each be replaced by a group which can be cleaved in vivo.
`
`
`
` By a group which can be cleaved in vivo from an imino or
`
`amino group is meant,
`
`
`for example,
`
`a hydroxy group, an acyl
`
`10
`
`15
`
`20
`
`295
`
`30
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`group such as the benzoyl or pyridinoyl group or a
`
`
`Ci-ig-alkanoyl group such as the formyl, acetyl, propionyl,
`
`butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl
`
`group,
`
`a Ci-41,-alkoxycarbonyl group such as the methoxy—
`
`carbonyl, ethoxycarbonyl, propoxycarbonyl,
`
`isopropoxycar-—
`
`
`
`bonyl, butoxycarbonyl,
`
`tert.butoxycarbonyl, pentoxycarbo-—
`
`nyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl,
`
`
`
`
`
`decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl or
`
`hexadecyloxycarbonyl group, a phenyl—-Ci-«-alkoxycarbonyl
`
`group such as the benzyloxycarbonyl, phenylethoxycarbonyl
`
`or phenylpropoxycarbonyl group, a C;,-3-alkylsulphonyl-—
`
`
`
`
`
`
`
`
`
`
`Co-a-alkoxycarbonyl, Ci-3s-alkoxy-—C2-4a-alkoxy-
`
`Coa-alkoxycarbonyl or R.CO-O- (ReCR,) -O-CO group wherein
`
`
`
`R. denotes a Ci-s-alkyl, Cs-j-cycloalkyl, phenyl or phenyl-
`
`Ci-3-alkyl group,
`
`Re denotes a hydrogen atom,
`
`a Cy_-3-alkyl, Csj7-cycloalkyl or
`
`phenyl group and
`
`
`
`
`
`Rg denotes a hydrogen atom,
`
`a Ci-z,-alkyl or ReCO—-O- (R¢CRg)—-O
`
`
`group wherein R, to R, are as hereinbefore defined,
`
`wherein additionally the amino group may be a phthalimido
`
`group, whilst the abovementioned ester groups may also be
`
`used as a group which can be converted in vivo into a
`
`carboxy group.
`
`
`
`
`
`formula I which
`One sub-group of compounds of general
`
`deserves special mention comprises those wherein
`
`
`
`
`
`
`X, R1, and R3 to Rs are as hereinbefore defined and
`
`10
`
`15
`
`20
`
`295
`
`30
`
`

`

`
`
`
`
`
`
`WO 2006/067165
`
`PCT/EP2005/057002
`
`R. denotes a straight-chain or branched C)-,.-alkoxy—carbonyl
`
`group,
`
`a Cy_,;-cycloalkoxycarbonyl or a aryloxycarbonyl
`
`group,
`
`a straight-chain or branched Ci-¢-alkoxy—carbonyl group,
`
`which is terminally substituted in the alkyl moiety by a
`
`phenyl, heteroaryl, carboxy, C,:-alkoxycarbonyl,
`
`aminocarbonyl, Ci-3-alkylaminocarbonyl or
`
`10
`
`di-(Ci-3-alkyl)-aminocarbonyl group,
`
`a straight-chain or branched C2z.6-alkoxy—carbonyl group,
`
`which is terminally substituted in the alkyl moiety by a
`
`
`
`chlorine atom or a hydroxy, Ci 3-alkoxy, amino,
`
`15
`
`Cy-3-alkylamino or di-(C,-3-alkyl)-amino group,
`
`the tautomers,
`
`the diastereomers,
`
`the enantiomers,
`
`the
`
`
`
`mixtures thereof and the salts thereof.
`
`20
`
`
`
`
`
`formula I which
`A second sub-group of compounds of general
`
`deserves special mention comprises those wherein
`
`
`
`X, Ri and Rz to R, are as hereinbefore defined and
`
`
`
`295
`
`Rz2 denotes an aminocarbonyl or methylaminocarbonyl group,
`
`
`
`an ethylaminocarbonyl group optionally substituted in the 2
`
`
`position of the ethyl group by a hydroxy or Ci-3-alkoxy
`
`group or a di-(Ci-2,-alkyl)-aminocarbonyl group,
`
`30
`
`the tautomers,
`
`the diastereomers,
`
`the enantiomers,
`
`the
`
`
`
`mixtures thereof and the salts thereof.
`
`

`

`WO 2006/067165
`
`PCT/EP2005/057002
`
`
`
`
`
`
`formula I which
`A third

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket